Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

Neurol Neuroimmunol Neuroinflamm 2018;5:e445. doi:10.1212/NXI.0000000000000445

In the Article "Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod" by M. Nakhaei-Nejad et al.¹, there are typographical errors in the Abstract, which should use “CD4⁺,” “CD8⁺,” “CD27⁺IgD⁻”, and “CD27⁺” rather than “CD41,” “CD81,” CD271IgD2,” and “CD271” as originally published. The publisher regrets the errors.

Reference
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

*Neurol Neuroimmunol Neuroinflamm* 2018;5;
DOI 10.1212/NXI.0000000000000445

This information is current as of January 31, 2018

Updated Information & Services

including high resolution figures, can be found at:
http://nn.neurology.org/content/5/2/e445.full.html

References

This article cites 1 articles, 0 of which you can access for free at:
http://nn.neurology.org/content/5/2/e445.full.html##ref-list-1

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints

Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus